AXL and sarcoma: Tumoral AXL expression at baseline (from tumor biopsies collected following disease progression on the last prior therapy) was generally low (≤15% median AXL+ tumor cells) in all cohorts except for sarcoma (68.8% median AXL+ tumor cells) (Table 2), a tumor type with known high intrinsic AXL expression.